Protalix BioTherapeutics Reports Third Quarter 2026 Financial and Business Results
Protalix BioTherapeutics, Inc. (PLX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Protalix BioTherapeutics Reports Third Quarter 2026 Financial and Business Results Company to host conference call and webcast today at 8:00 a.m. ET ● Total revenues increased by $32.0 million year to date to $75.6 million, from $43.6 million for the same perio
How this was made
The 30-second read
Why it matters
The earnings beat and reaffirmed guidance provide a modest catalyst; no new guidance lift, so price reaction may be muted.
Market read
Earnings release for a micro‑cap biotech; relevance primarily to specialty‑health investors.
What to watch
The $25M milestone from Chiesi and upcoming Phase 2 results for PRX‑115 could drive future upside beyond the current guidance.
Background
The filing is a Form 8‑K Item 2.02 earnings release for Protalix BioTherapeutics, a rare‑disease biotech listed on NYSE American.
Ticker impact
Protalix BioTherapeutics reported Q3 2026 revenue of $75.6M, net income of $4.0M and reaffirmed its 2026 revenue guidance of $78‑83M.
potential modest upside as investors digest the revenue beat and unchanged guidance
The company posted higher revenue and profit versus the prior year and confirmed it will meet its previously set revenue range, which typically limits downside pressure.
Market effects
Positive data for rare‑disease biopharma may lift peer sentiment in the niche biotech sector.
Limited to U.S. and Israeli markets where the company is listed and operates.
Minimal global impact beyond niche investors.
Counterpoint
If the market had priced in higher growth, reaffirming guidance could be seen as a lack of upside.
Key entities
- ExecutiveDror Bashan
President and CEO of Protalix BioTherapeutics, quoted on results.
- PartnerChiesi Global Rare Diseases
Commercial partner for Elfabrio and source of a $25M milestone.
